europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

How soon can we respond to COVID-19?

30/04/2020
BLOG
How soon can we respond to COVID-19?

How soon can we respond to COVID-19?

The development of a vaccine or an antiviral treatment is a long and complex process. So why are we hearing that a vaccine against COVID-19 may be ready in a year from now, or even sooner?

Typical development of a vaccine or antiviral

It usually takes anything from 10-15 years to fully develop a vaccine or antiviral and bring it to market, but what does that process entail?

The Research & Preclinical phase involves identifying active substances or approaches to dealing with a virus or disease. For biotechnology companies, this can involve using human genes and cells. By exploring our genetics, biotechnology can find workable materials which are used to develop treatments. The Research & Preclinical stage involves preparing a treatment for lab testing to gain preliminary insights into potential efficacy. This stage typically takes 2 years.

Clinical Trials are the longest part of the development process and take on average about 8 years to complete. In the case of viruses, the late clinical trial stages are particularly important to ensure that treatments do not make people sicker than the virus would. This is because vaccines rely on introducing extremely low dosages of a virus into our immune systems, so that our antibodies can develop defence mechanisms. Antivirals are treatments often developed using innovative biotechnologies. These could trigger immediate immune reactions in a COVID-19 infected patient which attack the virus directly, as opposed to vaccines that need to wait for a protective response to be triggered.

Market Authorisation has to be sought for a treatment in the EU. The European Medicines Agency generally take 210 days to issue a recommendation for market authorisation to the European Commission. There is also a fast-track process that can reduce this timeframe to 150 days. For an authorised treatment to become available to patients, treatment developers need to reach individual agreements with each EU Member State, a process which can take several years in the EU, and can vary greatly depending of the country.

Developing a vaccine or an antiviral for the coronavirus

The current strain of the coronavirus, COVID-19 (COronaVIrus Disease 2019), is closely related to previous coronavirus strains, such as SARS and MERS. When the new coronavirus was identified in China in January, scientists around the world were ready to respond and the entire genome of the virus was published within days. In fact, COVID-19 shares 80-90% of its genetic material with SARS. Nevertheless, there are still gaps in our knowledge of how coronaviruses work in general and what makes the new coronavirus so special. Biotechnology companies in particular have responded faster than ever in comparison to any emerging health threat in the past.

Because of the wealth of existing information already available, the Research and Preclinical development stage for the coronavirus has been intensively accelerated and existing research, diagnostics, and treatments have been recycled and repurposed.

Last week, initial clinical trials began on potential treatments for the coronavirus. Later trial phases will also likely be expedited. Potential vaccines from Johnson & Johnson and antivirals from Gilead provide promising examples which may quickly lead to novel treatments against the coronavirus. The European Medicines Agency recently gave recommendations on the use of Gilead's Remdesivir as part of compassionate use programmes in the EU, i.e. giving patients with a life-threatening disease and no available treatment options access to treatments that are still under development.

Whether having a vaccine or a novel treatment is possible in 12-18 months still needs to be confirmed, but no effort is being spared by the biotechnology industry to find solutions. Scientists, regulators, and governments are working together to ensure the solidarity and collaboration needed from all sides in this fight against COVID-19.

Sources:
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146780/
• https://www.ncbi.nlm.nih.gov/pubmed/23632307
• https://www.ema.europa.eu/en/from-lab-to-patient-timeline
• http://www.rfi.fr/en/science-and-technology/20200307-coronavirus-why-vaccine-will-takeleast-12-months
• https://www.businessinsider.com/jj-coronavirus-vaccine-research-timeline-andemergency-use-2020-3?r=US&IR=T
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654359/

Download the file below to read the full document.

How soon can we respond to COVID-19?


Download

2020_04_H_B_How-soon-can-we-respond-to-COVID-19Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies